Robert Dubin
Endocrinology, Diabetes & Metabolism · Venice, FLNPI 1417970138
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Eli Lilly at 58.1% of the total. 2025 is the largest year on record at $17,941, more than ten times the $252 reported in 2019.
Across 90 payments — averaging $214.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$11K
- Lilly USA, LLC$7K
- Novo Nordisk$249
- Xeris Pharmaceuticals, Inc.$168
- Insulet Corporation$116
- Sanofi-aventis U.S. LLC$109
- plus $708 from 19 others
Across 29 payments — averaging $13,670 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$373K
- Pfizer$21K
- AbbVie$2K
What the payments were for
- Speaking & faculty fees$6,60034%
- Travel & lodging$1,2156%
- Food & beverage$11,50160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 13 | $11,219 |
| Lilly USA, LLC | 11 | $6,748 |
| Novo Nordisk | 7 | $249 |
| Xeris Pharmaceuticals, Inc. | 6 | $168 |
| Insulet Corporation | 7 | $116 |
| Sanofi-aventis U.S. LLC | 6 | $109 |
| Bayer | 3 | $84 |
| Boehringer Ingelheim | 4 | $78 |
| Merck | 4 | $63 |
| Radius Health, Inc. | 3 | $50 |
| GRT US Holding, Inc. | 2 | $49 |
| Amgen(2 entities) | 3 | $48 |
| IBSA Pharma Inc. | 2 | $39 |
| Abbott | 2 | $38 |
| Medtronic(2 entities) | 2 | $36 |
| Dexcom, Inc. | 2 | $35 |
| Mannkind Corporation | 3 | $35 |
| Tandem Diabetes Care, Inc. | 2 | $31 |
| AstraZeneca | 2 | $25 |
| BETA Bionics, Inc. | 1 | $21 |
| AbbVie | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Boston Scientific | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,316 in reported general payments places this provider in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 34 | $44,913 |
| OzempicSemaglutide | 24 | $36,708 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $32,004 |
| TrulicityDulaglutide | 11 | $18,027 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $17,575 |
| HumalogInsulin Lispro | 11 | $5,233 |
| Novolog FlexpenInsulin Aspart | 13 | $4,151 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,476 |
| SynthroidLevothyroxine Sodium | 20 | $1,428 |
| Levothyroxine Sodium | 55 | $559 |
| Metformin Hcl ErMetformin Hcl | 28 | $193 |
| Metformin Hcl | 21 | $106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $78 | $44,91334 claims |
| Novo NordiskOzempic | $249 | $36,70824 claims |
| Lilly USA, LLCTrulicity, Humalog | $6,748 | $23,26022 claims |
| AbbVieSynthroid | $19 | $1,42820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Venice
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
- Misha DenhamCoral Gables$673K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.